

JPET #86082

## **A novel, long-acting agonist of glucose dependent insulintropic polypeptide (GIP) suitable for once daily administration in type 2 diabetes**

Nigel Irwin, Brian D. Green, Mark H. Mooney, Brett Greer, Patrick Harriott, Clifford J. Bailey, Victor A. Gault, Finbarr P.M. O'Harte and Peter R. Flatt

School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK (N.I., B.D.G., M.H.M., V.A.G., F.P.M.O'H., P.R.F.), School of Biology and Biochemistry, Queen's University of Belfast, Northern Ireland, UK (B.G.), Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, Dublin, Ireland (P.H.) and School of Life and Health Sciences, Aston University, Birmingham, UK (C.J.B.)

JPET #86082

**Running title:** A long-acting fatty acid derivatised analog of GIP

**Address correspondence to:** Professor P.R. Flatt, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine BT52 1SA, Northern Ireland, United Kingdom. Phone: 44 28 7032 4419; Fax: 44 28 7032 4965; E-mail: pr.flatt@ulster.ac.uk.

**Nonstandard Abbreviations:** area under the curve (AUC); glucose-dependent insulintropic polypeptide (GIP), dipeptidylpeptidase IV (DPP IV)

**Number of text pages:** 26

**Number of tables:** 0

**Number of Figures:** 9

**Number of references:** 40

**Abstract word count:** 205

**Introduction word count:** 653

**Discussion word count:** 1197

JPET #86082

## Abstract

Glucose-dependent insulintropic polypeptide (GIP) is a gastrointestinal hormone with a potential therapeutic role in type 2 diabetes. Rapid degradation by dipeptidylpeptidase IV (DPP IV) has prompted the development of enzyme-resistant N-terminally modified analogs, but renal clearance still limits *in vivo* bioactivity. In this study, we report long-term antidiabetic effects of a novel, N-terminally protected, fatty acid derivatized analog of GIP, *N*-AcGIP(LysPAL<sup>37</sup>) in obese diabetic (*ob/ob*) mice. Once daily injections of *N*-AcGIP(LysPAL<sup>37</sup>) over a 14 day period significantly decreased plasma glucose, glycated hemoglobin and improved glucose tolerance compared to *ob/ob* mice treated with saline or native GIP. Plasma insulin and pancreatic insulin content were significantly increased by *N*-AcGIP(LysPAL<sup>37</sup>). This was accompanied by a significant enhancement in the insulin response to glucose together with a notable improvement of insulin sensitivity. No evidence was found for GIP-receptor desensitization and the metabolic effects of *N*-AcGIP(LysPAL<sup>37</sup>) were independent of any change in feeding or body weight. Similar daily injections of native GIP did not affect any of the parameters measured. These data demonstrate, the ability of once daily injections of N-terminally modified, fatty acid derivatized analogs of GIP, such as *N*-AcGIP(LysPAL<sup>37</sup>), to improve diabetes control and to offer a new class of agents for the treatment of type 2 diabetes.

JPET #86082

## Introduction

Glucose dependent insulintropic polypeptide (GIP) secreted from intestinal K-cells in response to nutrient absorption is an important enteroinsular hormone capable of lowering blood glucose concentrations (Meier et al., 2002). In addition to enhancing insulin secretion, GIP has been shown to stimulate proinsulin gene transcription and translation (Wang et al., 1996), increase pancreatic  $\beta$  cell growth (Trumper et al., 2001), and inhibit pancreatic  $\beta$  cell apoptosis (Ehnes et al., 2003). Since GIP also displays antihyperglycemic actions through extrapancreatic effects on muscle, adipose and liver tissue (Yip et al., 1998), increasing attention has been devoted to its possible antidiabetic potential (Gault et al., 2003a). Moreover, because the insulintropic actions of GIP are glucose-dependent (Bailey and Flatt 1995), the risk of hypoglycemia, a major drawback with non-endogenous insulin-releasing drugs, is minimized (Collins 2002). Accordingly, an important opportunity currently exists to generate a safe and efficient GIP-based pharmaceutical agent for the treatment of type 2 diabetes (O'Harte et al., 2000; Hinke et al., 2002; O'Harte et al., 2002; Gault et al., 2002a; Gault et al., 2003b).

Despite its antihyperglycemic properties, rapid degradation of GIP in the circulation poses a major obstacle in the realization of any possible therapeutic potential for GIP. Thus, GIP is rapidly metabolized by the ubiquitous enzyme dipeptidylpeptidase IV (DPP IV) to release the N-terminal dipeptide Tyr<sup>1</sup>-Ala<sup>2</sup>, giving rise to the major degradation fragment GIP(3-42) (Kieffer et al., 1995). This N-terminally truncated peptide lacks biological activity and possibly serves as a GIP receptor antagonist *in vivo* (Gault et al., 2002b). Therefore, it is anticipated that the development of DPP IV resistant analogs of GIP would not only extend the biological half-life of the peptide but also curtail production of GIP(3-42), thereby alleviating possible GIP receptor antagonism. In addition to inactivation by DPP IV, GIP is also subject to rapid renal clearance (Meier et al., 2004a), thereby imposing further limitations on biological half-life and potential for type 2 diabetes therapy.

JPET #86082

In the past 6 years, a number of N-terminally modified analogs of GIP have been developed which exhibit profound resistance to DPP IV (O'Harte et al., 2000; O'Harte et al., 2002; Gault et al., 2002a; Gault et al., 2003b). Several of these, most notably those modified at Tyr<sup>1</sup> of GIP with an addition of an acetyl, glucitol, pyroglutamyl or Fmoc adduct, exhibit enhanced activity at the GIP receptor *in vitro* (O'Harte et al., 2002; Gault et al., 2002a; Gault et al., 2003b; O'Harte et al., 1998). As a result of degradation resistance and enhanced cellular activity, these analogs display enhanced and protracted antihyperglycemic and insulin-releasing activity when administered acutely to animals with genetically-inherited obesity-diabetes (O'Harte et al., 2000; O'Harte et al., 2002; Gault et al., 2002a; Gault et al., 2003b). To increase potency and generate a long-acting GIP analog, possibly suitable for once daily injection in diabetes, the problem of renal clearance needs to be overcome. We have designed, therefore, a novel analog of GIP, namely *N*-AcGIP(LysPAL<sup>37</sup>), based on the premise that fatty acid derivatization will counter renal clearance by promoting binding of the peptide to albumin. Such a strategy has been shown to prolong the half-life of insulin (Kurtzhals et al., 1995) and the sister incretin glucagon-like peptide-1 (GLP-1) (Knudsen et al., 2000; Kim et al., 2003; Green et al., 2004).

The present study was designed to examine the ability of long-term treatment with *N*-AcGIP(LysPAL<sup>37</sup>) to counter the glucose intolerance and related features exhibited by obese diabetic (*ob/ob*) mice, a commonly employed animal model of type 2 diabetes (Bailey and Flatt 1982). *N*-AcGIP(LysPAL<sup>37</sup>), native GIP or saline as control, were administered once daily by intraperitoneal injection for 14 days prior to evaluation of glucose homeostasis, pancreatic  $\beta$  cell function and insulin sensitivity. Furthermore, possible desensitization of GIP receptor action by prolonged exposure to elevated concentrations of *N*-AcGIP(LysPAL<sup>37</sup>) was examined. The results indicate significant antidiabetic potential for this second generation *N*-

JPET #86082

terminally acetylated GIP analog containing a C-16 palmitate group linked to Lys at position 37.

JPET #86082

## Methods

**Animals.** Obese diabetic (*ob/ob*) mice derived from the colony maintained at Aston University, UK (23) were used at 14-17 weeks of age. Animals were housed in an air-conditioned room at 22±2°C with a 12 h light: 12 h dark cycle (08:00 – 20:00 h). Drinking water and standard rodent maintenance diet (Trouw Nutrition, Cheshire, UK) were freely available. All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986. No adverse effects were observed following long-term administration of GIP or *N*-AcGIP(LysPAL<sup>37</sup>).

**Synthesis, purification and characterization of GIP and *N*-AcGIP(LysPAL<sup>37</sup>).** Native GIP was sequentially synthesized on an Applied Biosystems automated peptide synthesizer (Model 432 A, Foster City, CA, USA) using standard solid-phase Fmoc peptide chemistry as previously reported (O'Harte et al., 2002). *N*-AcGIP(LysPAL<sup>37</sup>) was sequentially synthesized in the same way but with the exception that the lysine residue at position 37 was conjugated to an Fmoc protected C-16 palmitate fatty acid. The synthetic peptides were judged pure by reversed-phase HPLC on a Waters Millennium 2010 chromatography system (Software version 2.1.5) and subsequently characterized using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry as described previously (Gault et al., 2002c). The molecular masses of GIP and *N*-AcGIP(LysPAL<sup>37</sup>) were 4982.4 Da and 5267.7 Da, respectively. These were within 1-2 Da of the theoretical masses indicating successful peptide synthesis. Biological potency of both peptides was confirmed by acute *in vivo* tests (Fig. 1).

**Effects of GIP and *N*-AcGIP(LysPAL<sup>37</sup>) in *ob/ob* mice.** Initially, extended biological activity of *N*-AcGIP(LysPAL<sup>37</sup>) was examined in fed *ob/ob* mice in comparison with *N*-AcGIP and native GIP. Over a 14-day period, groups of *ob/ob* mice received once daily intraperitoneal

JPET #86082

injections (17:00 h) of either saline vehicle (0.9%, w/v, NaCl), native GIP or *N*-AcGIP(LysPAL<sup>37</sup>) (both at 12.5 nmoles/kg body weight/day). This dose was chosen on the basis of preliminary experiments that showed significant antihyperglycaemic and insulinotropic activity of *N*-AcGIP(LysPAL<sup>37</sup>) over the range 6.25 – 25 nmoles/kg, when administered acutely with glucose (18 mmol/kg) (Fig. 1). Food intake and body weight were recorded daily from 5 days before commencement of the treatment regimes. Plasma glucose and insulin concentrations (10:00h) were monitored at 2-6 day intervals. At 14 days, groups of animals were used to evaluate intraperitoneal glucose tolerance (18 mmol/kg) and insulin sensitivity (50 U/kg). In a separate series, two experimental protocols were employed to examine the possibility of GIP receptor desensitization after 14 days treatment. Acute metabolic effects of the usual injection of either saline, GIP or *N*-AcGIP(LysPAL<sup>37</sup>) were monitored when administered together with glucose (18 mmol/kg). In the second, acute effects of *N*-AcGIP(LysPAL<sup>37</sup>) given together with glucose were examined in all 3 groups of mice. All acute tests were commenced at 10:00 h. At the end of the 14-day treatment period, pancreatic tissues were excised for measurement of insulin following extraction with 5 ml/g ice-cold acid ethanol (75% ethanol, 2.35% H<sub>2</sub>O, 1.5% HCl). Whole blood was taken for determination of glycated hemoglobin. All other blood samples were collected from the cut tip of the tail vein of conscious mice into chilled fluoride/heparin coated glucose microcentrifuge tubes (Sarstedt, Nümbrecht, Germany) at the times indicated in the Figures. Blood samples were immediately centrifuged using a Beckman microcentrifuge (Beckman Instruments, Galway, Ireland) for 30 s at 13,000 g. The resulting plasma was then aliquoted into fresh tubes and stored at -20°C prior to glucose and insulin determinations.

**Biochemical analyses.** Plasma glucose was assayed by an automated glucose oxidase procedure (O'Harte et al., 2002) using a Beckman Glucose Analyzer II. Plasma and pancreatic



JPET #86082

insulin was assayed by dextran-charcoal RIA as described previously (O'Harte et al., 2002). Glycated hemoglobin was determined using cation-exchange columns (Sigma, Poole, Dorset, UK) with measurement of absorbance (415 nm) in wash and eluting buffers using a VersaMax microplate spectrophotometer (Molecular Devices, Wokingham, Berkshire, UK).

**Statistics.** Results are expressed as mean  $\pm$  SEM. Data were compared using the unpaired Student's t-test. Where appropriate, data were compared using repeated measures ANOVA or one-way ANOVA, followed by the Student-Newman-Keuls *post hoc* test. Incremental areas under plasma glucose and insulin curves (AUC) were calculated using a computer-generated program employing the trapezoidal rule (O'Harte et al., 2002) with baseline subtraction. Groups of data were considered to be significantly different if  $p < 0.05$ .

## Results

**Persistent glucose homeostatic effects of *N*-AcGIP(LysPAL<sup>37</sup>).** As shown in Figure 2, administration of *N*-AcGIP(LysPAL<sup>37</sup>) decreased the glycaemic excursion and glucose levels for up to 24h after administration with glucose to fed *ob/ob* mice (32% reduction;  $p < 0.05$ ). In comparison, the glucose homeostatic effects of *N*-AcGIP were relatively short lived (27% reduction at 1h;  $p < 0.05$ ) and native GIP lacked any effect on circulating glucose at the time points studied. This supports a protracted biological half-life of *N*-AcGIP(LysPAL<sup>37</sup>) and forms the basis of the once-daily injections.

**Effects of *N*-AcGIP(LysPAL<sup>37</sup>) on food intake, body weight, glycated hemoglobin and non-fasting plasma glucose and insulin concentrations.** Administration of GIP or *N*-AcGIP(LysPAL<sup>37</sup>) had no effect on food intake or body weight (Fig. 3a, b). Plasma glucose and insulin concentrations were also unchanged by treatment with native GIP for 14 days (Fig. 4a, b). In contrast, daily injection of *N*-AcGIP(LysPAL<sup>37</sup>) resulted in a progressive lowering of plasma glucose, resulting in significantly ( $p < 0.05$ ) lowered concentrations at 14 days (Fig. 4a). At this time, glycated hemoglobin was also significantly ( $p < 0.01$ ) decreased in *N*-AcGIP(LysPAL<sup>37</sup>) treated *ob/ob* mice (Fig. 4c). These changes were accompanied by a tendency towards elevated insulin concentrations, but these did not achieve statistical significance over the time frame studies (Fig. 4b).

**Effects of *N*-AcGIP(LysPAL<sup>37</sup>) on glucose tolerance.** Consistent with effects on glycated hemoglobin, treatment of *ob/ob* mice for 14 days with *N*-AcGIP(LysPAL<sup>37</sup>) resulted in a significant improvement in glucose tolerance (Fig. 5a). Plasma glucose concentrations throughout the test and the overall 0-60 min AUC values were decreased ( $p < 0.01$  to  $p < 0.001$ ). This was accompanied by increased insulin concentrations during the latter stages ( $p <$

JPET #86082

0.05) and a greater ( $p < 0.01$ ) overall AUC insulin response (Fig. 5b). In contrast, daily administration of native GIP had no effect on glucose tolerance or the plasma insulin response to glucose compared with control *ob/ob* mice receiving saline injections for 14 days (Fig. 5).

**Effect of *N*-AcGIP(LysPAL<sup>37</sup>) on insulin sensitivity.** Insulin sensitivity of the 3 groups of mice after 14 days treatment is shown in Fig. 6. Compared with *ob/ob* mice receiving daily injections of saline or native GIP, *N*-AcGIP(LysPAL<sup>37</sup>) prompted a significant improvement of insulin sensitivity. Both the individual glucose concentrations and 0-60 min AUC values were significantly different ( $p < 0.05$ ) from the other two groups. In contrast, daily treatment with native GIP did not affect the characteristic insulin resistance of *ob/ob* mice (Fig. 6).

**Evaluation of GIP receptor desensitization.** As shown in Fig. 7, treatment of *ob/ob* mice with *N*-AcGIP(LysPAL<sup>37</sup>) for 14 days did not prevent the ability of the peptide to significantly moderate the glycemic excursion ( $p < 0.01$ ) and enhance plasma insulin concentrations ( $p < 0.01$ ) when administered acutely with intraperitoneal glucose. In contrast, the responses of *ob/ob* mice to acute administration of native GIP were almost identical in mice receiving treatment with GIP or saline for 14 days (Fig. 7). To further substantiate the lack of GIP receptor desensitization following chronic treatment with *N*-AcGIP(LysPAL<sup>37</sup>), the acute effects of the analog, administered with glucose, were examined in each of the 3 groups after 14 days treatment with *N*-AcGIP(LysPAL<sup>37</sup>), native GIP or saline (Fig. 8). Apart from lower basal values in the former group, the glucose and insulin responses were identical with similar 0-60 min AUC measures for both plasma glucose and insulin concentrations.

**Effects of *N*-AcGIP(LysPAL<sup>37</sup>) on pancreatic insulin content.** Treatment of *ob/ob* mice for 14 days with native GIP or *N*-AcGIP(LysPAL<sup>37</sup>) did not affect pancreatic weight compared

JPET #86082

with saline-treated controls (Fig. 9a). Similarly, pancreatic insulin content was similar in the GIP and saline treated groups. However, daily administration of *N*-AcGIP(LysPAL<sup>37</sup>) significantly increased ( $p < 0.01$ ) insulin content compared with each of the other groups (Fig. 9b).

JPET #86082

## Discussion

In common with the sister incretin hormone GLP-1 (Meier and Nauck 2004), great effort has been devoted in recent years to generate stable long-acting analogs of GIP for potential use in the therapy of type 2 diabetes (Gault et al., 2003a; Gault et al., 2003c). This approach supposes that selected GIP analogs can overcome any defect of GIP action in diabetes. The prospect for this is encouraging in that the once postulated specific defect in GIP stimulation of insulin secretion in diabetes (Nauck et al., 1993) is now recognized to represent one aspect of a generalized pancreatic  $\beta$  cell dysfunction that extends to many secretagogues including incretin hormones (Kjems et al., 2003, Meier et al., 2003a). Additionally, DPP IV resistant N-terminally modified analogs of GIP have been shown to induce a protracted insulin response in both animals and humans with type 2 diabetes (O'Harte et al., 2000; Lindsay et al., 2002; O'Harte et al., 2002; Gault et al., 2002a; Gault et al., 2003b).

In the present study, we have examined the ability of a second generation N-terminally modified GIP analog to counter aspects of the *ob/ob* syndrome in mice (Bailey and Flatt 1982). The analog *N*-AcGIP was chosen for secondary modification by fatty acid derivatization to extend half-life and bioavailability by binding to albumin, thereby decreasing renal filtration. *N*-AcGIP has already been shown to exhibit profound DPP IV resistance, enhanced ability to stimulate cyclic AMP production and insulin secretion *in vitro* together with substantial antihyperglycemic and insulin releasing action in *ob/ob* mice *in vivo* (O'Harte et al., 2002). Further modification of GIP to carry a C-16 palmitate fatty acid at the  $\epsilon$ -amino group of the naturally occurring Lys at position 37 has been shown to conserve these attributes (O'Harte et al., 2004). At the same time *N*-AcGIP(LysPAL<sup>37</sup>) exhibits extended action in acute tests making it suitable for exploration as a possible once daily treatment using animal models of diabetes.

JPET #86082

Administration of *N*-AcGIP(LysPAL<sup>37</sup>) to young adult *ob/ob* mice by daily intraperitoneal injection resulted in a progressive lowering of plasma glucose concentrations and a significant decrease of glycated hemoglobin by 14 days. This was associated with a substantial improvement of glucose tolerance. Importantly food intake and body weight were unchanged during the study ruling out the possibility that improvement of glucose homeostasis was merely the consequence of body weight loss. These observations also indicate that *N*-AcGIP(LysPAL<sup>37</sup>) was not associated with body weight gain and did not exert any untoward toxic actions affecting feeding over the study period. This is in harmony with recent studies showing that GIP, unlike the sister incretin GLP-1, does not inhibit gastric emptying (Meier et al., 2003b). Daily administration of native GIP to *ob/ob* mice for 14 days had no effect on any of the parameters measured, consistent with the very short half-life of the native GIP *in vivo* (Holz et al., 1993).

As expected, a key component of the beneficial action of *N*-AcGIP(LysPAL<sup>37</sup>) concerned the stimulation of insulin secretion. Thus although native GIP is a weak stimulus to insulin secretion in *ob/ob* mice at the age studied, plasma and pancreatic insulin concentrations were raised in *ob/ob* mice receiving the novel fatty acid derivatized analog. This is consistent with the action of GIP as a promoter of proinsulin gene expression (Wang et al., 1996) and exemplifies the increased potency reported for N-terminally modified GIP analogs in animal models of diabetes (O'Harte et al., 2000; Hinke et al., 2002; O'Harte et al., 2002; Gault et al., 2002a; Gault et al., 2003b). Furthermore, the insulin response to glucose was significantly enhanced in *ob/ob* mice receiving *N*-AcGIP(LysPAL<sup>37</sup>). This ability to augment or restore pancreatic beta cell glucose responsiveness in diabetes has been similarly observed with GLP-1 (Holz et al., 1993). As with observations on glycemic control, none of these attributes were reproduced by daily injections of native GIP.

JPET #86082

Results of insulin sensitivity tests conducted after 14 days treatment indicate that the improvement of diabetic status achieved in *ob/ob* mice with *N*-AcGIP(LysPAL<sup>37</sup>) was not solely due to the potentiation of insulin secretion. Thus, these animals also exhibited a significant improvement of insulin sensitivity compared to the GIP or saline treated groups. Given that hyperinsulinemia is generally believed to down-regulate insulin receptor function, this suggests that *N*-AcGIP(LysPAL<sup>37</sup>) may exert other compensatory effects. Further study is necessary to evaluate this aspect but possibilities include inhibition of counter-regulatory hormones and effects on extrapancreatic sites such as muscle, adipose tissue and liver (Yip et al., 1998).

Irrespective of knowledge of the full range of actions contributing to the antihyperglycemic effect of *N*-AcGIP(LysPAL<sup>37</sup>), a currently envisaged problem of long-term treatment with stable analogs of GIP or GLP-1 concerns desensitization of hormone receptor action (Delmeire et al., 2004). Although this has been observed during prolonged exposure of pancreatic  $\beta$  cells to GIP during culture *in vitro* (Tseng et al., 1996), there was no evidence that treatment with *N*-AcGIP(LysPAL<sup>37</sup>) for 14 days compromised the glucose lowering or insulin releasing actions of *N*-AcGIP(LysPAL<sup>37</sup>) in any way. Thus the antidiabetic actions of *N*-AcGIP(LysPAL<sup>37</sup>) were clearly evident when the analog was administered acutely together with glucose. Furthermore, the acute effects of *N*-AcGIP(LysPAL<sup>37</sup>) in such experiments were identical in groups of *ob/ob* mice receiving either *N*-AcGIP(LysPAL<sup>37</sup>), native GIP or saline injections for 14 days.

Such data clearly indicate that prolonged exposure to *N*-AcGIP(LysPAL<sup>37</sup>) does not induce and possibly overcomes inherent GIP receptor desensitization in *ob/ob* mice. Given the high circulating concentrations of GIP in these obese-diabetic rodents (Flatt et al., 1983; Flatt et al., 1984), it is tempting to link  $\beta$  cell refractoriness to GIP evident in *ob/ob* mice and reported

JPET #86082

in some individuals with clinical diabetes (Ebert et al., 1979) to simple receptor desensitization at the hands of inappropriate secretion and metabolism of GIP. This is supported by the recent observation that the insulin response to intravenous bolus injection of GIP was effectively preserved in patients with type 2 diabetes whereas continuous intravenous infusion induced a poor response (Meier et al., 2004b). However, present appreciation of the role of circulating GIP in clinical diabetes is far from complete. This is due to lack of specificity of radioimmunoassays for active as opposed to the predominant inactive metabolite GIP(3-42). However it is quite reasonable to consider that the latter truncated form of GIP as a receptor antagonist (Gault et al., 2002b) might actively contribute to the reported down-regulation of GIP receptor function on pancreatic  $\beta$  cells in diabetes.

In conclusion, these studies indicate that once daily injection of *N*-AcGIP(LysPAL<sup>37</sup>) to *ob/ob* mice for 14 days results in a significant amelioration of diabetes and associated metabolic disturbances. Such effects are independent of changes in feeding and body weight. The antidiabetic actions appear to be mediated by enhancement of both pancreatic  $\beta$  cell function and insulin sensitivity, although other possible extrapancreatic actions may exist. Development of antibodies against analogs of naturally circulating peptides such as *N*-AcGIP(LysPAL<sup>37</sup>) is also likely to be minimized by the minor structural changes undertaken, as evidenced by the use of insulin analogues (Bolli 2003). Overall, these novel observations provide strong encouragement for the development of long-acting fatty acid derivatized N-terminally modified analogs of GIP, such as *N*-AcGIP(LysPAL<sup>37</sup>), for the once-daily treatment of type 2 diabetes.



JPET #86082

## References

- Bailey CJ and Flatt PR (1982) Influence of genetic background and age on the expression of the obese hyperglycemic syndrome in Aston *ob/ob* mice. *Int J Obesity* **6**:11-21.
- Bailey CJ and Flatt PR (1995) Development of antidiabetic drugs. In *Drugs, diet and disease: mechanistic approaches to diabetes*. (C. Ioannides, and P.R. Flatt, eds.) pp. 279-326, Ellis Horwood. London.
- Bolli GB (2003) Insulin treatment and its complications. In *Textbook of Diabetes*, 3<sup>rd</sup> Edition. (J.C. Pickup and G Williams, eds). pp.43.01-43.20, Blackwell Science Ltd. Oxford.
- Collins FM (2002) Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings. *Am J Manag Care* **8**:S460-471.
- Deacon CF, Nauck MA, Meier J, Hucking K and Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. *J Clin Endocrinol Metab* **85**:3575-3581.
- Delmeire D, Flamez D, Moens K, Hinke SA, Van Schravendiik C, Pipeleers D and Schuit F (2004) Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. *Biochem Pharmacol* **68**:33-39.
- Ebert R, Frerichs H and Creutzfeldt, W. (1979) Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance. *Eur J Clin Invest* **9**:129-135.
- Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, Pederson RA and McIntosh CHS (2003) Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. *Endocrinology* **144**:4433-4445.

JPET #86082

Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V (1983) Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. *Diabetes* **32**:433-435.

Flatt PR, Bailey CJ, Kwasowski P, Page T and Marks V (1984) Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (*ob/ob*) mice. *J Endocrinol* **101**:249-256.

Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, Mooney MH and O'Harte FPM (2002a) Enhanced cyclic AMP generation and insulin-releasing potency of two novel N-terminal Tyr<sup>1</sup>-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. *Biochem J* **367**:913-920.

Gault VA, Parker JC, Harriott P, Flatt PR and O'Harte FPM (2002b) Evidence that the major degradation product of glucose-dependent insulintropic polypeptide (GIP), GIP(3-42), is a GIP receptor antagonist *in vivo*. *J Endocrinol* **175**:525-533.

Gault VA, Irwin N, Harriott P, Flatt PR and O'Harte FPM (2002c) DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulintropic polypeptide, (Ser<sup>2</sup>-Asp<sup>13</sup>)GIP. *Cell Biol Int* **27**:41-46.

Gault VA, Flatt PR and O'Harte FPM (2003a) Glucose-dependent insulintropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. *Biochem Biophys Res Commun* **308**:207-213.

Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ and O'Harte FPM (2003b) Improved biological activity of Gly<sup>2</sup>- and Ser<sup>2</sup>-substituted analogues of glucose-dependent insulintropic polypeptide. *J Endocrinol* **176**:133-141.

Gault VA, O'Harte FPM and Flatt PR (2003c) Glucose-dependent insulintropic polypeptide (GIP): anti-diabetic and anti-obesity potential? *Neuropeptides* **37**:253-263.

Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FPM and Flatt PR (2004) Degradation, receptor binding, insulin secreting and

JPET #86082

antihyperglycaemic actions of palmitate-derivatised native and Ala<sup>8</sup>-substituted GLP-1 analogues. *Biol Chem* **385**:169-177.

Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU and McIntosh CH (2002) Dipeptidyl peptidase IV-resistant [D-Ala<sup>2</sup>]glucose-dependent insulintropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. *Diabetes* **51**:656-661.

Holz GG, Kuhtreiber WM and Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulintropic hormone glucagon-like peptide-1(7-37). *Nature* **28**:362-365

Kieffer TJ, McIntosh CH and Pederson RA (1995) Degradation of glucose-dependent insulintropic polypeptide and truncated glucagon-like peptide-1 *in vitro* and *in vivo* by dipeptidyl peptidase IV. *Endocrinology* **136**:3585-3596.

Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C and Drucker DJ (2003) Development and characterization of a glucagon-like peptide-1 albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor *in vivo*. *Diabetes* **52**:751-759.

Kjems LL, Holst JJ, Volund A and Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. *Diabetes* **52**:380-386.

Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M and Agersø H (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. *J Med Chem* **43**:1664-1669.

Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U and Markussen J (1995) Albumin binding of insulins acylated with fatty acids: characterization of the ligand-

JPET #86082

protein interaction and correlation between binding affinity and timing of the insulin effect *in vivo*. *Biochem J* **312**:725-731.

Lindsay JR, Au STB, Kelly CMN, O'Harte FPM, Flatt PR and Bell PM (2002) A novel amino-terminally glycosylated analogue of glucose-dependent insulinotropic polypeptide (GIP), with prolonged insulinotropic activity in type 2 diabetes mellitus. *Diabetes* **51**:A85 (Abstr.).

Meier JJ, Nauck MA, Schmidt WE and Gallwitz B (2002) Gastric inhibitory polypeptide: the neglected incretin revisited. *Regul Pept* **107**:1-13.

Meier JJ and Nauck MA (2004) The potential role of glucagon-like peptide 1 in diabetes. *Curr Opin Investig Drugs* **5**:402-410.

Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaekler D, Schmidt WE and Gallwitz B (2004a) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. *Diabetes* **53**:654-662.

Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE and Nauck MA (2004b) Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. *Diabetes* **53**:(Suppl 3) 220-224.

Meier JJ, Nauck MA, Siepmann N, Greulich M, Holst JJ, Deacon CF, Schmidt WE and Gallwitz B (2003a) Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. *Metabolism* **52**:1579-1585.

Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B and Nauck MA (2003b) Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. *Am J Phys Endocrinol Metab* **286**:E621-625.

JPET #86082

- Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R and Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest* **91**:301-307.
- O'Harte FPM, Abdel-Wahab YHA, Conlon JJ and Flatt PR (1998) Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. *Biochem Biophys Acta* **1425**:319-327.
- O'Harte FPM, Mooney MH, Kelly CMN and Flatt PR (2000) Improved glycaemic control in obese diabetic *ob/ob* mice using N-terminally modified gastric inhibitory polypeptide. *J Endocrinol* **165**:639-648.
- O'Harte FPM, Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ and Flatt PR (2002) Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. *Diabetologia* **45**:1281-1291.
- O'Harte FPM, Irwin N, Gault VA, Green BD and Flatt PR (2004) Assessment of the antidiabetic potential of two fatty acid derivatised GIP analogues. *Regul Pept* **122**:A105 (Abstr.).
- Trumper A, Trumper K, Trusheim H, Arnold R, Goke B and Horsch D (2001) Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. *Mol Endocrinol* **15**:1559-1570.
- Tseng CC, Boylan MO, Jarboe LA, Usdin TB and Wolfe MM (1996) Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. *Am J Physiol* **270**:E661-E666.

JPET #86082

Wang Y, Montrose-Rafizadeh C, Adams L, Raygada M, Nadiv O and Egan JM (1996) GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. *Mol Cell Endocrinol* **116**:81-87.

Yip RG, Boylan MO, Kieffer TJ and Wolfe MM (1998) Functional GIP receptors are present on adipocytes. *Endocrinology* **139**:4004-4007.

JPET #86082

## **Footnotes**

These studies were supported by University of Ulster Research Strategy Funding and a Project Grant from Diabetes UK.

Reprint requests: Professor Peter R. Flatt, School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, BT52 1SA.

JPET #86082

## Figure Legends

**Fig. 1.** Acute glucose homeostatic and insulin releasing effects of *N*-AcGIP(LysPAL<sup>37</sup>) and native GIP. Glucose (18 mmol/kg) was administered by intraperitoneal injection alone or in combination with 6.25, 12.5 or 25 nmol/kg *N*-AcGIP(LysPAL<sup>37</sup>) or 12.5 nmol/kg native GIP at the time indicated by the arrow. Plasma glucose and insulin AUC values for 0-60 min post injection are shown in the right panels. Values are mean  $\pm$  SEM for 8 mice. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  compared to mice receiving glucose alone.

**Fig. 2.** Persistent glucose-homeostatic effects of *N*-AcGIP(LysPAL<sup>37</sup>). Plasma glucose concentrations were measured prior to and after intraperitoneal injection of fed *ob/ob* mice with glucose (18 mmol/kg body weight) alone or in combination with 12.5 nmol/kg body weight *N*-AcGIP(LysPAL<sup>37</sup>), *N*-AcGIP or native GIP. The arrow indicates the time after which access to food was withdrawn. Values represent means  $\pm$  SEM for 6 mice. \* $p < 0.05$  compared to mice injected with glucose alone.

**Fig. 3.** Effects of daily *N*-AcGIP(LysPAL<sup>37</sup>) administration on food intake (A) and body weight (B). *N*-AcGIP(LysPAL<sup>37</sup>) (12.5 nmol/kg/day), native GIP (12.5 nmol/kg/day) or saline vehicle (control) were administered for the 14-day period indicated by the horizontal black bar. Values are mean  $\pm$  SEM for 8 mice.

**Fig. 4.** Changes of plasma glucose (A), insulin (B) and final glycated hemoglobin (C) after daily treatment of *ob/ob* mice with *N*-AcGIP(LysPAL<sup>37</sup>) (12.5 nmol/kg/day), native GIP



JPET #86082

(12.5 nmoles/kg/day) or saline vehicle (control) for 14 days. Values are mean  $\pm$  SEM for 8 mice.  $*p < 0.05$ ,  $**p < 0.01$  compared to control.  $\Delta\Delta p < 0.01$  compared to native GIP.

**Fig. 5.** Effects of daily *N*-AcGIP(LysPAL<sup>37</sup>) administration on glucose tolerance and plasma insulin response to glucose. Tests were conducted after 14 daily injections of either *N*-AcGIP(LysPAL<sup>37</sup>) (12.5 nmoles/kg/day), native GIP (12.5 nmoles/kg/day) or saline vehicle (control). Glucose (18 mmol/kg) was administered by intraperitoneal injection at the time indicated by the arrow. Plasma glucose and insulin AUC values for 0-60 min post injection are shown in the right panels. Values are mean  $\pm$  SEM for 8 mice.  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$  compared to control.  $\Delta p < 0.05$ ,  $\Delta\Delta p < 0.01$ ,  $\Delta\Delta\Delta p < 0.001$  compared to native GIP.

**Fig. 6.** Effects of daily *N*-AcGIP(LysPAL<sup>37</sup>) administration on insulin sensitivity. Tests were conducted after 14 daily injections of either *N*-AcGIP(LysPAL<sup>37</sup>) (12.5 nmoles/kg/day), native GIP (12.5 nmoles/kg/day) or saline vehicle (control). Insulin (50 U/kg) was administered by intraperitoneal injection at the time indicated by the arrow. Plasma glucose AUC values from baseline for 0-60 min post injection are shown in the right panels. The starting values for saline, GIP and *N*-AcGIP(LysPAL<sup>37</sup>) were  $16.3 \pm 2.0$ ,  $15.7 \pm 1.7$ ,  $13.9 \pm 2.4$  mmol/l, respectively. Values are mean  $\pm$  SEM for 8 mice.  $*p < 0.05$ ,  $**p < 0.01$  compared to control.  $\Delta p < 0.05$  compared to native GIP.

**Fig. 7.** Retention of glucose homeostatic and insulin releasing activity of *N*-AcGIP(LysPAL<sup>37</sup>) and native GIP after daily injection for 14 days. Glucose (18 mmol/kg) was administered by intraperitoneal injection alone or in combination with either *N*-AcGIP(LysPAL<sup>37</sup>) or native GIP (both at 25 nmoles/kg) at the time indicated by the arrow. Plasma glucose and insulin AUC

JPET #86082

values for 0-60 min post injection are shown in the right panels. Values are mean  $\pm$  SEM for 8 mice.  $*p < 0.05$ ,  $**p < 0.01$  compared to glucose alone.  $^{\Delta}p < 0.05$ ,  $^{\Delta\Delta}p < 0.01$  compared to native GIP.

**Fig. 8.** Acute glucose homeostatic and insulin releasing effects of *N*-AcGIP(LysPAL<sup>37</sup>) after 14 daily injections of either *N*-AcGIP(LysPAL<sup>37</sup>) (12.5 nmoles/kg/day), native GIP (12.5 nmoles/kg/day) or saline vehicle (control). *N*-AcGIP(LysPAL<sup>37</sup>) (25 nmoles/kg) was administered by intraperitoneal injection with glucose (18 nmoles/kg) at the time indicated by the arrow. Plasma glucose and insulin AUC values for 0-60 min post injection are shown in the right panels. Values are mean  $\pm$  SEM for 8 mice.  $*p < 0.05$ ,  $**p < 0.01$  compared to mice receiving control injections.  $^{\Delta}p < 0.05$ ,  $^{\Delta\Delta}p < 0.01$  compared to group receiving injections of native GIP.

**Fig. 9.** Effects of daily *N*-AcGIP(LysPAL<sup>37</sup>) administration on pancreatic weight and insulin content. Parameters were determined after 14 daily injections of *N*-AcGIP(LysPAL<sup>37</sup>) (12.5 nmoles/kg/day), native GIP (12.5 nmoles/kg/day) or saline vehicle (control). Values are mean  $\pm$  SEM for 8 mice.  $**p < 0.01$  compared to control.  $^{\Delta\Delta}p < 0.01$  compared to native GIP.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6






Fig. 7




Fig. 8




Fig. 9

